PACIRA BIOSCIENCES INC (PCRX) Stock Fundamental Analysis
NASDAQ:PCRX - US6951271005 - Common Stock
26.61 USD
+0.31 (+1.18%)
26.61 USD
0 (0%)
Overall PCRX gets a fundamental rating of 5 out of 10. We evaluated PCRX against 195 industry peers in the Pharmaceuticals industry. PCRX has only an average score on both its financial health and profitability. PCRX is cheap, but on the other hand it scores bad on growth. These ratings could make PCRX a good candidate for value investing.
1. Profitability
1.1 Basic Checks
PCRX had positive earnings in the past year.
PCRX had a positive operating cash flow in the past year.
PCRX had positive earnings in 4 of the past 5 years.
Each year in the past 5 years PCRX had a positive operating cash flow.
1.2 Ratios
PCRX's Return On Assets of -8.29% is fine compared to the rest of the industry. PCRX outperforms 68.72% of its industry peers.
With a decent Return On Equity value of -16.82%, PCRX is doing good in the industry, outperforming 70.77% of the companies in the same industry.
PCRX has a better Return On Invested Capital (3.88%) than 81.03% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PCRX is significantly below the industry average of 15.28%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.29% | ||
| ROE | -16.82% | ||
| ROIC | 3.88% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.17%
ROIC(5y)4.47%
1.3 Margins
PCRX has a Operating Margin of 9.90%. This is amongst the best in the industry. PCRX outperforms 82.56% of its industry peers.
In the last couple of years the Operating Margin of PCRX has grown nicely.
PCRX's Gross Margin of 78.19% is amongst the best of the industry. PCRX outperforms 84.62% of its industry peers.
In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.9% | ||
| PM (TTM) | N/A | ||
| GM | 78.19% |
OM growth 3Y-17.2%
OM growth 5Y10.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PCRX is destroying value.
Compared to 1 year ago, PCRX has less shares outstanding
The number of shares outstanding for PCRX has been increased compared to 5 years ago.
The debt/assets ratio for PCRX is higher compared to a year ago.
2.2 Solvency
PCRX has an Altman-Z score of 1.67. This is a bad value and indicates that PCRX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PCRX (1.67) is better than 63.08% of its industry peers.
The Debt to FCF ratio of PCRX is 4.96, which is a neutral value as it means it would take PCRX, 4.96 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.96, PCRX belongs to the top of the industry, outperforming 83.59% of the companies in the same industry.
PCRX has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
PCRX has a Debt to Equity ratio of 0.50. This is comparable to the rest of the industry: PCRX outperforms 40.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.96 | ||
| Altman-Z | 1.67 |
ROIC/WACC0.45
WACC8.66%
2.3 Liquidity
PCRX has a Current Ratio of 2.38. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
PCRX has a Current ratio (2.38) which is in line with its industry peers.
A Quick Ratio of 1.91 indicates that PCRX should not have too much problems paying its short term obligations.
PCRX has a Quick ratio of 1.91. This is comparable to the rest of the industry: PCRX outperforms 44.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.38 | ||
| Quick Ratio | 1.91 |
3. Growth
3.1 Past
The earnings per share for PCRX have decreased by -1.92% in the last year.
Measured over the past years, PCRX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.96% on average per year.
The Revenue for PCRX has decreased by -17.68% in the past year. This is quite bad
PCRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.73% yearly.
EPS 1Y (TTM)-1.92%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-16.85%
Revenue 1Y (TTM)-17.68%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%1.73%
3.2 Future
PCRX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.92% yearly.
The Revenue is expected to grow by 6.56% on average over the next years.
EPS Next Y-9.95%
EPS Next 2Y1.81%
EPS Next 3Y6.01%
EPS Next 5Y5.92%
Revenue Next Year5.46%
Revenue Next 2Y7.74%
Revenue Next 3Y8.08%
Revenue Next 5Y6.56%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 8.70, which indicates a very decent valuation of PCRX.
Compared to the rest of the industry, the Price/Earnings ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 91.79% of the companies listed in the same industry.
PCRX is valuated cheaply when we compare the Price/Earnings ratio to 27.03, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 8.00, which indicates a rather cheap valuation of PCRX.
90.26% of the companies in the same industry are more expensive than PCRX, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.54. PCRX is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.7 | ||
| Fwd PE | 8 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaply inside the industry as 92.82% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, PCRX is valued cheaper than 91.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.21 | ||
| EV/EBITDA | 7.32 |
4.3 Compensation for Growth
The decent profitability rating of PCRX may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.62
EPS Next 2Y1.81%
EPS Next 3Y6.01%
5. Dividend
5.1 Amount
No dividends for PCRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
26.61
+0.31 (+1.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners111.46%
Inst Owner Change0.2%
Ins Owners0.8%
Ins Owner Change0.71%
Market Cap1.20B
Analysts76.92
Price Target38.15 (43.37%)
Short Float %14.25%
Short Ratio9.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.06%
Min EPS beat(2)1.99%
Max EPS beat(2)2.13%
EPS beat(4)4
Avg EPS beat(4)5.22%
Min EPS beat(4)1.99%
Max EPS beat(4)9.93%
EPS beat(8)5
Avg EPS beat(8)3.99%
EPS beat(12)6
Avg EPS beat(12)-0.53%
EPS beat(16)8
Avg EPS beat(16)-3.68%
Revenue beat(2)0
Avg Revenue beat(2)-4.46%
Min Revenue beat(2)-5.92%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-2.98%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.49%
Revenue beat(12)1
Avg Revenue beat(12)-2.62%
Revenue beat(16)1
Avg Revenue beat(16)-2.55%
PT rev (1m)-4.1%
PT rev (3m)-3.11%
EPS NQ rev (1m)-2.15%
EPS NQ rev (3m)-25.51%
EPS NY rev (1m)-2.34%
EPS NY rev (3m)0.51%
Revenue NQ rev (1m)-0.66%
Revenue NQ rev (3m)-0.21%
Revenue NY rev (1m)-0.5%
Revenue NY rev (3m)-0.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.7 | ||
| Fwd PE | 8 | ||
| P/S | 1.69 | ||
| P/FCF | 10.21 | ||
| P/OCF | 8.89 | ||
| P/B | 1.58 | ||
| P/tB | 3.8 | ||
| EV/EBITDA | 7.32 |
EPS(TTM)3.06
EY11.5%
EPS(NY)3.33
Fwd EY12.5%
FCF(TTM)2.61
FCFY9.79%
OCF(TTM)2.99
OCFY11.25%
SpS15.71
BVpS16.87
TBVpS7.01
PEG (NY)N/A
PEG (5Y)0.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.29% | ||
| ROE | -16.82% | ||
| ROCE | 5.71% | ||
| ROIC | 3.88% | ||
| ROICexc | 6.11% | ||
| ROICexgc | 14.17% | ||
| OM | 9.9% | ||
| PM (TTM) | N/A | ||
| GM | 78.19% | ||
| FCFM | 16.59% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.17%
ROIC(5y)4.47%
ROICexc(3y)5.86%
ROICexc(5y)7.17%
ROICexgc(3y)13.2%
ROICexgc(5y)24.66%
ROCE(3y)6.13%
ROCE(5y)6.57%
ROICexcg growth 3Y-34.27%
ROICexcg growth 5Y13.31%
ROICexc growth 3Y-4.56%
ROICexc growth 5Y9.22%
OM growth 3Y-17.2%
OM growth 5Y10.42%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score5
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.96 | ||
| Debt/EBITDA | 2.36 | ||
| Cap/Depr | 19.4% | ||
| Cap/Sales | 2.47% | ||
| Interest Coverage | 4.34 | ||
| Cash Conversion | 84.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.38 | ||
| Quick Ratio | 1.91 | ||
| Altman-Z | 1.67 |
F-Score5
WACC8.66%
ROIC/WACC0.45
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.92%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-16.85%
EPS Next Y-9.95%
EPS Next 2Y1.81%
EPS Next 3Y6.01%
EPS Next 5Y5.92%
Revenue 1Y (TTM)-17.68%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%1.73%
Revenue Next Year5.46%
Revenue Next 2Y7.74%
Revenue Next 3Y8.08%
Revenue Next 5Y6.56%
EBIT growth 1Y-39.89%
EBIT growth 3Y-9.76%
EBIT growth 5Y22.27%
EBIT Next Year1.75%
EBIT Next 3Y12.4%
EBIT Next 5Y6.85%
FCF growth 1Y-7.53%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-8.67%
OCF growth 3Y14.64%
OCF growth 5Y21.85%